Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOBBY: Brolucizumab vs Aflibercept in Chinese nAMD
NCT04047472Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2019
- Primary completion
- Feb 2024
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Nov 2019; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04047472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047472.